Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients

Journal of Hypertension

Volumn 18, Issue 8, 2000, Pages 1019-1023

  Januszewicz, Andrzej ^a   Neumann, Hartmut P H ^b   Łoń, Izabella ^c   Szmigielski, Cezary ^c   Symonides, Bartosz ^c   Kabat, Marek ^a   Apel, Thomas W ^b   Wocial, Bozenna ^c   Łapiński, Mariusz ^c   Januszewicz, Wodzimierz ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b UNIVERSITY OF FREIBURG   (Germany)

^c MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Genetic testing; Multiple endocrine neoplasia; Pheochromocytoma; RET proto oncogene

Indexed keywords

ADRENALIN; CALCITONIN; CARCINOEMBRYONIC ANTIGEN; NORADRENALIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; DIAGNOSTIC TEST; FEMALE; GENE MUTATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; THYROID MEDULLARY CARCINOMA;

EID: 0033850902     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200018080-00005     Document Type: Article

References (24)

1. Clinical manifestations
2. Pheochromocytoma (with a preface about incidental adrenal masses)
3. Pheochromocytoma - The catecholamine dependent hypertension
4. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia type II
5. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprungs disease
6. Inherited pheochromocytoma
7. The RET proto-oncogene and cancer
8. RET proto-oncogene mutations and endocrine neoplasia - A story intertwined with neural crest differentiation
9. Germline mutation of the RET proto-oncogene in multiple endocrine neoplasia type 2 A
10. Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC
11. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
12. Functioning thoracic paraganglioma: Association with von Hippel-Lindau syndrome
13. Pheochromocytomas, multiple endocrine neoplasia type 2 and von Hippel-Lindau disease
14. Clinical and biochemical aspects of pheochromocytoma. Report of 110 cases
15. Plasma erythropoietin concentration in patients with pheochromocytoma
16. Plasma atrial natriuretic peptide (ANP) concentration in patients with pheochromocytoma
17. Pheochromocytoma in multiple endocrine neoplasia type 2: European study
18. Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2 A, MEN 2 B and FMTC: Two novel mutations and one de novo mutation for MEN 2 A
19. Mutations of the RET proto-oncogene in German Multiple Endocrine Neoplasia families: Relation between genotype and phenotype
20. Genetic alterations of the RET proto-oncogene in familial and sporadic pheochromocytomas
21. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic pheochromocytoma
22. Extensive mutation scanning of RET in sporadic medullary thyroid carcinoma and of RET and VHL in sporadic pheochromocytoma reveals involvement of these genes in only a minority of cases
23. Sporadic pheochromocytomas are rarely associated with germline mutations in the von Hippel-Lindau and RET genes
24. The RET proto-oncogene in sporadic pheochromocytomas frequent MEN 2 like mutations and new molecular defects